*Refresh the page if the below document does not appear.
Indian Pharma sector set for "Volume to value leadership journey" in the year 2023
In the new year, reinventing and innovating will be the main mantras of the Indian pharma industry. The industry also emerging as the ‘pharmacy of the world’ looks to move forward from volume to value leadership amidst the rising pricing pressures and inflation issues.
Maiden Pharma cough syrup case: Gambian authorities seek legal action
The Maiden Pharma’s cough syrup case has been bought to light again in Gambia. According to BBC, a parliamentary committee in Gambia has suggested “prosecution of an Indian manufacturer of cough syrups suspected of killing at least 70 children in the West African country” .
FDA updates Cancer drug approval process, pharma majors willing to fall in line
Recently, a change in FDA’s cancer drug practice was observed when GSK pulled an accelerated approval for the multiple myeloma drug Blenrep at the request of the FDA just 15 days after revealing a confirmatory trial failure. The fact showed a major makeover happening in the FDA’s oncology department.
USFDA gives final approval to Lupin Pharma's Seizure tablets
Global Drugmaker Lupin Pharma on Wednesday declared that it has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg strength.
Glenmark Pharma observes 6% rise after launching type 2 Diabetes drug
On Wednesday, shares of Glenmark Pharmaceuticals rose nearly 6% in intraday trade, in contrast with the observations before the launch of Zita‐PioMet, the country’s first triple fixed-dose combination for high insulin‐resistant type 2 diabetes.
Beijing Covid curbs might affect API supplies, fears Himachal pharma firms
As the number of Covid cases is rising in China, it is making some Indian Pharma firms fear the disruption in API (Active Pharmaceutical Ingredient) supplies in India, as over 65% of API is imported from the neighboring countries.
Glenmark launches triple FDC of Teneligliptin with Pioglitazone, Metformin in India
Glenmark pharmaceuticals Limited has
launched the first-of-its-kind triple fixed-dose
combination of Teneligliptin with Pioglitazone,
and Metformin in India. This FDC has come to
the market with a brand name of Zita-PioMet
containing the three drugs in a sustained
release (SR) formulation.
